MARKET

ANL

ANL

Adlai Nortye Ltd.
NASDAQ
13.94
+0.79
+6.01%
After Hours: 13.94 0 0.00% 16:10 05/13 EDT
OPEN
12.96
PREV CLOSE
13.15
HIGH
14.08
LOW
12.82
VOLUME
42.11K
TURNOVER
--
52 WEEK HIGH
17.25
52 WEEK LOW
0.8786
MARKET CAP
739.90M
P/E (TTM)
-12.5461
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ANL last week (0504-0508)?
Weekly Report · 3d ago
Adlai Nortye files initial beneficial ownership statement for Kaiyang Tang, Adlai Nortye USA president
PUBT · 5d ago
Weekly Report: what happened at ANL last week (0427-0501)?
Weekly Report · 05/04 09:22
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 04/30 12:06
Adlai Nortye: Recapitalized, Refocused, But Still Too Early To Upgrade
Seeking Alpha · 04/29 22:14
Adlai Nortye files Form 3 as director Ping Ji reports no beneficial ownership
PUBT · 04/29 13:35
Weekly Report: what happened at ANL last week (0420-0424)?
Weekly Report · 04/27 09:23
BRIEF-Adlai Nortye Files For Mixed Shelf Offering Of Up To $600 Million
Reuters · 04/23 10:37
More
About ANL
Adlai Nortye Ltd. is a global clinical-stage biotechnology company. The Company is involved in the research and development of pharmaceutical products. It is a clinical-stage company focused on the development of targeted and immune-modulating cancer therapies. It is advancing an oncology pipeline, with Buparlisib (AN2025), a pan-phosphoinositide 3-kinase (PI3K) inhibitor, being evaluated in a registrational Phase three trial (NCT04338399) for patients with recurrent or metastatic head and neck squamous cell cancer (HNSCC) that has progressed after prior anti-programmed death-ligand 1 (PD-L1) treatment. It is also advancing multiple drug candidates, including AN4005, an oral small molecule PD-L1 inhibitor; AN8025, a multifunctional fusion protein acting as a T cell and antigen-presenting cell (APC) modulator; and AN9025, an oral small molecule pan-rat sarcoma virus (RAS) inhibitor and AN4035, a Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (CEACAM5).

Webull offers Adlai Nortye Ltd (ADR) stock information, including NASDAQ: ANL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ANL stock methods without spending real money on the virtual paper trading platform.